PAUL SYLVAIN: Open Payments
NPI 1992132187 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$758 in 24 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $56 · 2025 $758
Food & beverage: $758
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $233 |
| Merck Sharp & Dohme LLC | 6 | $150 |
| Kowa Pharmaceuticals America, Inc. | 1 | $125 |
| Mannkind Corporation | 1 | $109 |
| AstraZeneca Pharmaceuticals LP | 3 | $78 |
| Agios Pharmaceuticals, Inc. | 1 | $29 |
| Amgen Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
Products named: Rybelsus, ZORYVE, AFREZZA, FARXIGA, LAGEVRIO, VERQUVO, Ozempic, PYRUKYND.
Industry payments across NY — which companies pay providers there.
